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Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder resulting from mutations in the NF1 gene. 
NF1 encodes the protein neurofibromin, which negatively 
regulates p21Ras (Ras) activity via stimulation of its GTPase 
function.1 Germline mutations causing NF1 affect only 1 NF1 
allele, although the loss of heterozygosity is described in pri-
mary tumor samples from NF1 patients.2 Thus, haploinsuffi-
ciency of NF1 results in disease with complete penetrance and 
diverse clinical manifestations in different organ systems.
Clinical Perspective on p 1224
Common nonneoplastic manifestations of NF1 include 
cognitive disorders and skeletal abnormalities,2 whereas car-
diovascular disease (CVD) is a serious but underrecognized 
complication, contributing to significant increases in mor-
bidity and premature mortality.3,4 In particular, the aorta and 
proximal branches demonstrate increased aneurysm forma-
tion and exaggerated intimal hyperplasia.5 The frequency of 
NF1 vasculopathy is difficult to define because of a lack of 
routine screening; however, the prevalence of vascular lesions 
in large clinical series approaches 7%.5–7 Specifically, a study 
of 31 NF1 patients with a diagnosis of vascular disease identi-
fied 38 aneurysms among the group, with an average age at 
diagnosis of 38 years (range, 3–77).5
Studies using mouse models that recapitulate NF1 
 vaso-occlusive disease revealed that neurofibromin-deficient 
myeloid cells and vascular smooth muscle cells (VSMCs) 
cooperate to induce neointima hyperplasia after arterial 
injury.8–10 Correlative studies demonstrate that NF1 patients 
have evidence of chronic inflammation and mobilization of a 
specific monocyte subset in their peripheral blood that is linked 
to vaso-occlusive disease progression and aneurysm formation 
in non-NF1 patients with CVD.8,11 Despite these observations, 
the pathogenesis of NF1 aneurysm disease is unknown, in 
part, because of a lack of animal models that mimic the human 
disease. Given the mostly silent presentation of aneurysms in 
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1214  Circulation  March 18, 2014
NF1 patients and the potential for catastrophic rupture, under-
standing disease pathogenesis is critical for aneurysm preven-
tion, early detection, and treatment.
In this study, we used an established mouse model of aneu-
rysm formation and cell lineage–restricted transgenic mice 
to test the role of Nf1 haploinsufficiency (Nf1+/–) in vari-
ous cell types on aneurysm formation. We provide evidence 
that heterozygous inactivation of Nf1 directly contributes to 
larger and more severe aneurysms with enhanced oxidative 
species production and matrix metalloproteinase-9 (MMP-9) 
activation. Further, lineage-restricted inactivation of a single 
Nf1 gene copy in myeloid cells, but not VSMCs, is sufficient 
for aneurysm formation, thereby implicating Nf1+/– myeloid 
cells as the cellular triggers for Nf1+/– aneurysm formation in 
vivo. Finally, we provide pharmacological evidence that aneu-
rysm formation in Nf1+/– mice is abrogated by daily low-dose 
administration of the 3-hydroxy-3-methylglutaryl coenzyme 
A reductase inhibitor simvastatin, which has antioxidant and 
anti-inflammatory effects. To further delineate the pharmaco-
logical effects of simvastatin, Nf1+/– mice were treated with 
the antioxidant apocynin, which also reduced aneurysm for-
mation. Thus, we generated a novel model of NF1-associated 
aneurysmal disease and provide genetic evidence that Nf1+/– 
myeloid cells are critical mediators of aneurysm formation 
via an antioxidant-sensitive pathway, suggesting a potential 
therapeutic target.
Methods
Animals
All protocols were approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee. Nf1+/– 
mice were obtained from Tyler Jacks (Massachusetts Institute of 
Technology, Cambridge) and backcrossed 13 generations into the 
C57BL/6J strain. Nf1flox/flox mice were obtained from Luis Parada 
(University of Texas Southwestern Medical Center, Dallas) and 
backcrossed 13 generations into the 129SvJ strain. LysMcre (stock 
4781) and SM22cre (stock 4746) mice were purchased from Jackson 
Laboratory (Bar Harbor, ME). Nf1fl/fl mice were intercrossed with 
LysMcre or SM22cre mice to generate F1 C57BL/6×129SvJ 
progeny. Cre-mediated recombination was confirmed by poly-
merase chain reaction.12 LacZ lineage tracing of aortas from 
Nf1fl/+;Rosa26fl/+;Sm22cre mice revealed staining limited to the vessel 
media where VSMCs reside (data not shown). LacZ lineage tracing 
of aortas from Nf1fl/+;Rosa26fl/+;LysMcre mice revealed sparse stain-
ing limited to the vessel adventitia (data not shown). Nf1fl/fl 129SvJ 
mice intercrossed with Nf1+/– C57BL/6 mice generated F1 Nf1+/– and 
 wild-type (WT) control animals. Genotyping was performed as previ-
ously described.9
Angiotensin II–Infused Abdominal Aortic 
Aneurysm Model
Twelve-week-old control and experimental male mice were infused 
with angiotensin II (AngII, 1500 ng∙kg–1∙min–1, Calbiochem) or saline 
for 35 days, as described,13 with modification. Animals were anes-
thetized by inhalation of 2% isoflurane, and an osmotic pump (2006, 
Durect Corporation) containing AngII or saline was implanted subcu-
taneously. At indicated time points, a portion from the aortic arch to 
the iliac arteries was excised for analysis.
Classification and Quantification of Aneurysms
Images of arteries were obtained on a stereo-microscope (Carl Zeiss 
Inc). The maximum external arterial diameters were measured using 
Metamorph 6.1 (Universal Imaging Systems Corp). Aneurysms were 
defined as an increase in the external aortic diameter of ≥50% in 
comparison with control animals. Aortic aneurysm severity was rated 
from type 0 to type IV according to the method of Martin-McNulty 
et al14 with modification: type 0, no aneurysm; type I, dilation 1.5 to 2 
times the diameter of a normal artery; type II, a single dilation that is 
>2 times the diameter of a normal artery; type III, multiple dilations 
with the largest being 1.5 to 2 times the diameter of a normal artery; 
and type IV, multiple dilations with the largest being >2 times the 
diameter of a normal artery.
Simvastatin and Apocynin Administration
Simvastatin (1 mg∙kg–1∙d–1, Besse) was administered in water via oral 
gavage beginning 7 days before AngII or saline infusion and contin-
ued throughout the experiment. Apocynin (also known as acetovanil-
lone, 100 mg∙kg–1∙d–1, Acros Organics) was administered in drinking 
water beginning 7 days before AngII or saline infusion and continued 
throughout the experiment. Control mice received water at a similar 
volume.
Statistical Analysis
Quantitative results are shown as mean±standard error of the mean. 
All statistical analyses were performed by using Prism 5 (GraphPad 
Software). P values were obtained by the unpaired Student t test when 
comparing 2 groups and by 1-way analysis of variance followed by 
Tukey analysis when comparing ≥3 groups. P<0.05 was considered 
significant. To determine the significance of categorical data, the 
Fisher exact test was used with Bonferroni correction.
Results
Heterozygous Inactivation of Nf1 Amplifies the 
Incidence and Severity of Aneurysm Formation in 
Angiotensin II–Infused Mice
To test the hypothesis that Nf1 heterozygosity enhances aneu-
rysm formation in vivo, WT and Nf1+/– mice were infused with 
AngII to induce aneurysms. The infusion of AngII induces 
inflammatory mediators and reactive oxygen species (ROS) 
within the arterial wall, producing abdominal aortic aneu-
rysms (AAA) that recapitulate human lesions.15
Infusion of AngII increased aneurysm formation 3-fold in 
Nf1+/– mice in comparison with WT mice (Figure 1A and 1B). 
Morphometric analysis of abdominal aortas from both geno-
types revealed that AngII-infused Nf1+/– mice had significantly 
larger aneurysms (Figures 1C and 2A). Further, Nf1+/– aneu-
rysms were more severe than WT aneurysms quantitatively, 
with increased degradation of the elastic lamina and disor-
ganized architecture, which is reminiscent of lesions from 
NF1 patients (Figures 1D, 2B, and 2D).16 Importantly, AngII 
infusion did not alter body weight or intra-arterial blood pres-
sure in either genotype (data not shown). Saline-infused Nf1+/– 
and WT mice did not form aneurysms (Figures 1A, 1B, and 
2A). These data indicate that Nf1 heterozygosity augments 
 AngII-induced aneurysm formation.
Nf1+/– Aneurysms Are Characterized by 
Inflammatory Cell Infiltration, VSMC Expansion, 
and ROS Production
NF1 patients and Nf1+/– mice have increased populations of 
circulating inflammatory monocytes and proinflammatory 
cytokines linked to aneurysm formation.8,9 Therefore, we 
sought to characterize the cellular and structural composi-
tion of WT and Nf1+/– aneurysms. Histological examination 
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of Nf1+/– aneurysms demonstrated significant dilation and 
degradation of the aorta, including increased disruption of the 
elastic lamina and adventitial expansion in comparison with 
WT aneurysms (Figure 2A through 2E). Importantly, Nf1+/– 
aneurysms contained 4 times the number of macrophages in 
comparison with WT (Figure 2C and 2E). Infiltrating T cells, 
mast cells, and neutrophils were increased in both Nf1+/– and 
WT aneurysms, but accounted for <5% of all cells and did 
not differ between genotypes (data not shown). Importantly, 
Nf1+/– macrophages colocalized to sites of elastic lamina deg-
radation, medial rupture, and adventitial expansion, indicat-
ing their potential role in aneurysm formation (Figure 2B and 
2C). AngII infusion also induced a significant expansion of 
VSMCs in the media of Nf1+/– aortas in comparison with WT 
(Figure IA and IB in the online-only Data Supplement). Nf1+/– 
VMSC expansion is consistent with previous findings that 
Nf1+/– VSMCs exhibit increased proliferation and migration 
in response to cytokines secreted by macrophages and vascu-
lar wall cells implicated in CVD.9,17 Finally, costaining with 
α-smooth muscle actin and anti-Mac-3 illustrated that VSMC 
expansion was within and near the vessel media, whereas 
macrophage infiltration was primarily in the adventia (Figure 
IC in the online-only Data Supplement).
Genetic studies demonstrate that VSMC and macrophage 
secretion of MMPs and ROS are important molecular triggers 
for extracellular matrix remodeling and aneurysm induction.18 
Figure 1. Nf1+/– mice have enhanced AngII-induced AAA formation. A, Representative photographs of the aorta and branches from saline- 
or AngII-infused WT and Nf1+/– mice. Boxes identify the areas magnified in the lower photographs. Scale bars, 1 mm. B, Quantification of 
aneurysm incidence. *P<0.0083 for saline-infused WT (n=24) vs AngII-infused WT (n=29) and AngII-infused Nf1+/– (n=31). **P<0.0083 for 
saline-infused Nf1+/– (n=16) vs AngII-infused Nf1+/–. Analysis by Fisher exact test with Bonferroni correction. C, Maximum abdominal aortic 
diameter of saline- or AngII-infused WT and Nf1+/– mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 
for saline-infused Nf1+/– (n=16) vs AngII-infused Nf1+/– (n=31). **P<0.05 for AngII-infused WT (n=29) vs AngII-infused Nf1+/– (n=31). No 
statistical significance was observed for saline-infused WT (n=24) vs AngII-infused WT (n=29). Analysis by 1-way ANOVA with the Tukey 
test. Error bars=mean±SEM. D, Aneurysm severity for AngII-infused WT (n=29) or AngII-infused Nf1+/– (n=31) mice. No aneurysms formed 
in saline-infused mice of either genotype. AAA indicates abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; 
SEM, standard error of the mean; and WT, wild type.
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Given the increased density of VSMCs and macrophages in 
Nf1+/– aneurysms, we measured expression and activation of 
MMP-2 and MMP-9 in aortas harvested from Nf1+/– and WT 
mice infused with AngII or saline. AngII infusion increased 
both MMP-2 and MMP-9 activity and preferentially ampli-
fied MMP-9 expression in Nf1+/– aneurysms in comparison 
with AngII-infused WT aneurysms as determined by in situ 
zymography and immunohistochemistry (Figure 3A). In 
addition, gelatin zymography of abdominal aortic explants 
from  AngII-infused WT and Nf1+/– mice corroborated increases 
of MMP-2 and MMP-9 in both genotypes with significantly 
enhanced activation of MMP-9 in Nf1+/– aortas (Figure 3B). 
Amplified MMP-9 expression in Nf1+/– aortas is an important 
observation, because MMP-9 is largely derived from vessel 
wall macrophages,19 which is consistent with the increased 
macrophage infiltration observed in Nf1+/– aneurysms.
Figure 2. Histological and 
morphometric analysis of 
abdominal aortas from WT and 
Nf1+/– mice. Representative 
photomicrographs of 
abdominal aortic  cross-
sections from saline- and 
AngII-infused WT and Nf1+/– 
mice stained with hematoxylin 
and eosin (A), van Gieson (B), 
or anti–Mac-3 antibody (C; 
arrowheads). Boxed areas 
are magnified in the lower 
photographs. Arrowheads 
in B indicate elastic lamina 
fragmentation. Scale bars, 
50 μm. D, Grading of elastic 
lamina degradation in 
saline- or AngII-infused WT 
and Nf1+/– mice. *P<0.05 for 
saline-infused Nf1+/– (n=5) or 
WT (n=5) vs AngII-infused 
Nf1+/– mice (n=13). **P<0.05 
for AngII-infused WT (n=15) 
vs AngII-infused Nf1+/– mice. 
No statistical significance was 
observed for saline-infused 
WT or Nf1+/– vs AngII-infused 
WT. E, Quantification of 
Mac3-positive macrophages 
per high-power field in 
saline- or AngII-infused WT 
and Nf1+/– mice. *P<0.05 for 
saline-infused Nf1+/– (n=5) vs 
AngII-infused Nf1+/– mice (n=5). 
**P<0.05 for AngII-infused WT 
(n=5) vs AngII-infused Nf1+/– 
mice. No statistical significance 
was observed for  saline-
infused WT (n=5) vs  AngII-
infused WT. Analysis by 1-way 
ANOVA with the Tukey test. 
AngII indicates angiotensin II; 
ANOVA, analysis of variance; 
H/E, hematoxylin and eosin; 
and WT, wild type.
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We next assessed ROS production in abdominal aortic cross-
sections from AngII- and saline-infused Nf1+/– and WT mice 
with dihydroethidium, a superoxide probe. AngII infusion 
significantly increased superoxide production in Nf1+/– aortas 
in comparison with WT aortas, whereas superoxide produc-
tion was nearly undetectable in the aortas from  saline-infused 
Nf1+/– and WT aortas (Figure 3C and 3D). Collectively, these 
data demonstrate that Nf1 heterozygous aneurysms have 
evidence of increased inflammatory cell infiltration, MMP 
activation, and ROS production, which are linked to abnormal 
arterial remodeling and disease progression.
Heterozygous Inactivation of Nf1 in Myeloid  
Cells Alone Is Sufficient to Recapitulate Nf1+/– 
Aneurysm Formation
Nf1+/– mice have increased aneurysm formation character-
ized by increased macrophages and VSMCs and their secre-
tory products that promote disease progression. Based on 
Figure 3. AngII induces 
MMP-9 expression and 
activity and ROS production in 
Nf1+/– mice. A, Representative 
photomicrographs of 
abdominal aortic  cross-
sections from saline- and 
AngII-infused WT and 
Nf1+/– mice. MMP activity 
(green) was visualized by 
in situ zymography and 
expression of MMP-2 and 
MMP-9 was detected by 
immunohistochemistry 
staining with anti-MMP-2 
(brown) and anti-MMP-9 
(brown) antibodies. Scale bars, 
50 μm. B, Representative 
zymogram showing 
abdominal aortic MMP-2 
and MMP-9 levels for saline- 
and AngII-infused WT and 
Nf1+/– mice. C, Representative 
photomicrographs of 
abdominal aortic  cross-
sections from saline- or  AngII-
infused WT and Nf1+/– mice, 
showing superoxide production 
identified by in situ DHE 
staining (red). Autofluorescence 
of murine tissue is visible 
(green). D, Quantification of 
ethidium fluorescence. *P<0.05 
for AngII-infused Nf1+/– (n=9) 
vs saline-infused WT (n=5) 
and Nf1+/– (n=3). **P<0.05 
for AngII-infused Nf1+/– vs 
AngII-infused WT (n=8). AngII 
indicates angiotensin II; 
DHE, dihydroethidium; FLU, 
fluorescence; MMP, matrix 
metalloproteinase; ROS, 
reactive oxygen species; and 
WT, wild type.
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these observations, we generated transgenic mice with a 
single copy of the Nf1 gene ablated in VMSCs or myeloid 
cells alone to determine the role of Nf1 heterozygosity in 
VSMCs and macrophages on aneurysm formation. In brief, 
Nf1fl/fl mice containing conditional Nf1 alleles susceptible to 
Cre-mediated recombination were intercrossed with SM22cre 
or LysMcre transgenic mice, generating Nf1fl/+;SM22cre and 
Nf1fl/+;LysMcre progeny. Nf1fl/fl mice underwent efficient 
 Cre-mediated recombination when crossed with LysMcre 
(Figure IIF in the online-only Data Supplement) or SM22cre 
mice.10 LysMcre-mediated recombination was seen in the aor-
tic adventia, a known location for macrophages, whereas the 
aortic media showed minimal recombination.
Nf1fl/+;SM22cre and Nf1fl/+;LysMcre mice were infused with 
AngII or saline and evaluated for aneurysm formation along 
with littermate controls (WT and Nf1+/– mice). Nf1fl/+;LysMcre 
mice infused with AngII developed large aneurysms recapitu-
lating the phenotype of Nf1+/– mice, whereas Nf1fl/+;SM22cre 
mice produced less severe aneurysms similar to WT mice 
(Figure 4A through 4D). Specifically, a 2.5-fold increase in 
AAA incidence was observed in Nf1fl/+;LysMcre mice in com-
parison with Nf1fl/+;SM22cre and WT mice (Figure 4B). Saline 
infusion failed to produce aortic aneurysms in all genotypes 
(data not shown). Additionally, AngII-infused Nf1fl/+;LysMcre 
aneurysms displayed similar maximal dilation and aneurysm 
severity in comparison with Nf1+/– mice (Figure 4C and 4D).
Histological examination of hematoxylin and eosin– and 
van Gieson–stained arterial cross-sections of Nf1fl/+;LysMcre 
aneurysms revealed increased elastic lamina degradation 
and adventitial expansion, similar to aneurysms harvested 
from AngII-infused Nf1+/– mice (Figure IIA through IIC 
in the online-only Data Supplement). Cross-sections from 
Nf1fl/+;LysMcre aortas demonstrated increased macrophage 
density similar to Nf1+/– aneurysms, whereas Nf1fl/+;SM22cre 
and WT mice contained significantly reduced macrophage 
numbers (Figure 4E). Similar to Nf1+/– mice, macrophages in 
Nf1fl/+;LysMcre mice were in close proximity to areas of adven-
titial expansion and elastic lamina degradation (Figure 4E and 
Figure IIB in the online-only Data Supplement). Additionally, 
Nf1fl/+;LysMcre and Nf1fl/+;SM22cre displayed MMP activ-
ity and dihydroethidium staining similar to Nf1+/– and WT 
mice, respectively (Figure IID and IIE in the online-only Data 
Supplement). Collectively, these data provide genetic evi-
dence that heterozygous inactivation of Nf1 in myeloid cells 
alone is sufficient to recapitulate Nf1+/– aneurysm formation in 
vivo, thereby implicating Nf1+/– macrophages as the cellular 
trigger for aneurysm formation.
Simvastatin Attenuates AngII-Induced AAA 
Formation in Nf1+/– Mice
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors 
are clinically efficacious in the prevention of several mani-
festations of CVD, including aneurysm formation,20 which is 
in part attributable to their anti-inflammatory and antioxidant 
function.21 Recent studies have shown that daily statin therapy 
reduces arterial stenosis in Nf1+/– mice, in part, by inhibit-
ing macrophage functions central to disease progression.9 
Therefore, we tested whether simvastatin would reduce Nf1+/– 
aneurysm formation given our experimental observations.
WT and Nf1+/– mice were treated with daily low-dose simv-
astatin (1 mg∙kg–1∙d–1) or water for 7 days before the initiation 
of AngII infusion and continued for 35 days. Low-dose simv-
astatin reduced AAAs in AngII-infused Nf1+/– mice by >2-fold 
in comparison with water-treated controls (Figure 5A and 5B) 
without affecting blood pressure or serum cholesterol levels 
(data not shown). Corresponding decreases in aortic diameter 
and severity in AngII-infused Nf1+/– mice were also observed 
(Figure 5C and 5D). There was no significant difference in 
AAA incidence, maximum aortic diameter, or severity in 
AngII-infused WT mice in either treatment group (Figure 5A 
through 5D). Further, simvastatin treatment reduced arterial 
remodeling, macrophage infiltration (Figure IIIA and IIIB in 
the online-only Data Supplement) MMP-9 expression and 
activation, and ROS production (Figure IVA through IVD in 
the online-only Data Supplement) in arterial cross-sections 
from Nf1+/– mice in comparison with water treatment. These 
results demonstrate that simvastatin prevents AngII-induced 
AAA formation in Nf1+/– mice, providing a potential therapeu-
tic for NF1 aneurysmal disease.
Apocynin Attenuates AngII-Induced AAA 
Formation in Nf1+/– Mice
Increased production of ROS has been demonstrated in several 
animal models of CVD, and antioxidant therapy has shown 
some utility in reversing many of these processes.22 Based on 
our observation that Nf1+/– aortas have evidence of increased 
ROS in response to AngII infusion, we sought to explore the 
role of antioxidant therapy, using apocynin, in attenuating 
Nf1+/– aneurysm formation. Although generally recognized as 
a nonspecific antioxidant, recent evidence suggests that apoc-
ynin may inhibit superoxide production in cells containing 
myeloperoxidase, including macrophages and monocytes.23,24
WT and Nf1+/– mice were treated with apocynin for 7 days 
before initiation of AngII infusion and continued for 35 days 
thereafter. Apocynin reduced AAAs in AngII-infused Nf1+/– 
mice by >2-fold in comparison with water-treated controls, 
whereas apocynin did not have a significant effect on WT 
mice (Figure 6A and 6B). Additionally, decreases in both 
maximum abdominal aortic diameter and aneurysm sever-
ity were also noted in apocynin-treated Nf1+/– mice, whereas 
apocynin-treated WT mice did not display a difference in 
either parameter (Figure 6C and 6D). Remodeling of the arte-
rial wall, macrophage infiltration, and ROS production was 
significantly reduced in apocynin-treated Nf1+/– mice in com-
parison with water-treated controls (Figure VA through VD 
in the online-only Data Supplement). These results identify 
overproduction of ROS as a significant contributor to Nf1+/– 
aneurysm formation and provide evidence that antioxidants 
may be a viable therapeutic option.
Discussion
Cardiovascular disease is a nonneoplastic manifestation in 
NF1 patients that contributes to debilitating morbidities and 
early mortality.3,4 Many of these vascular pathologies, includ-
ing aneurysm formation and arterial stenosis, are often clini-
cally silent until a catastrophic event, making an accurate 
measure of disease burden difficult to determine. Thus, under-
standing the pathogenesis of NF1 vasculopathy is critical to 
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facilitate appropriate CVD screening, early recognition, and 
targeted intervention in NF1 patients.
A major limitation in understanding NF1 aneurysmal 
disease has been the lack of an animal model that closely 
recapitulates the human disease. In this study, we present a 
murine model of NF1 aneurysmal disease, which provides 
a novel approach to examine the cellular mechanisms that 
regulate NF1 aneurysm formation. Analysis of Nf1+/– aneu-
rysms revealed increased macrophage infiltration, MMP-9 
expression and activation, and ROS production, which are 
molecular and cellular signatures of aneurysm formation 
observed in other experimental animal models independent 
Figure 4. Heterozygous inactivation of Nf1 in myeloid cells alone is sufficient to recapitulate Nf1 aneurysm formation. A, Representative 
photographs of abdominal aortas from AngII-infused WT, Nf1+/–, Nf1flox/+;LysMcre and Nf1flox/+;SM22cre mice. Scale bars, 1 mm.  Saline-
infused WT, Nf1+/–, Nf1flox/+;LysMcre and Nf1flox/+;SM22cre mice did not form aneurysms (data not shown). B, Quantification of aneurysm 
incidence. C, Maximum abdominal aortic diameter of AngII-infused WT, Nf1+/–, Nf1flox/+;LysMcre and Nf1flox/+;SM22cre mice. Clustering 
around 1 mm represents animals without aneurysm formation. *P<0.05 for AngII-infused WT (n=10) vs AngII-infused Nf1+/– (n=9), and 
AngII-infused WT vs Nf1flox/+;LysMcre (n=15). **P<0.05 for AngII-infused Nf1flox/+;SM22cre (n=10) vs AngII-infused Nf1+/–, and AngII-
infused Nf1flox/+;SM22cre vs AngII-infused Nf1flox/+;LysMcre. Analysis by 1-way ANOVA with the Tukey test. Error bars=mean±SEM. For 
B and C, no statistical significance was observed for AngII-infused WT vs AngII-infused Nf1flox/+;SM22cre, or AngII-infused Nf1+/– vs 
AngII-infused Nf1flox/+;LysMcre. D, Severity index of aneurysms for AngII-infused WT (n=10), Nf1+/– (n=9), Nf1flox/+;LysMcre (n=15), and 
Nf1flox/+;SM22cre mice (n=10). E, Representative photomicrographs of abdominal aortic cross-sections from AngII-infused WT, Nf1+/–, 
Nf1flox/+;LysMcre, and Nf1flox/+;SM22cre mice stained with anti–Mac-3 (arrowheads). Boxes specify area magnified in lower photographs. 
Scale bars, 50 μm. AAA indicates abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error 
of the mean; and WT, wild type.
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of neurofibromin deficiency.19,25 These observations suggest 
that vascular inflammation and macrophage secretory prod-
ucts are critical factors in NF1 aneurysmal disease, which is 
consistent with aneurysm formation in other chronic inflam-
matory diseases.25,26 This is an important observation, because 
we previously demonstrated that NF1 patients without known 
CVD have increased numbers of a specific subset of circu-
lating inflammatory monocytes and cytokines8 that have been 
previously linked to vascular disease in non-NF1 subjects in 
large-population studies.11
Figure 5. Preventive effect of simvastatin on AngII-induced AAA formation in Nf1+/– mice. A, Representative photographs of abdominal 
aortas from water or simvastatin-treated, AngII-infused WT and Nf1+/– mice. Scale bars, 1 mm. B, Quantification of aneurysm incidence in 
water- or simvastatin-treated, AngII-infused mice. C, Maximum abdominal aortic diameter of water or simvastatin-treated, AngII-infused 
WT and Nf1+/– mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 for water-treated WT (n=17) vs 
water-treated Nf1+/– (n=22). **P<0.05 for water-treated Nf1+/– vs simvastatin-treated Nf1+/– (n=10). Analysis by 1-way ANOVA with the 
Tukey test. Error bars=mean±SEM. For B and C, no statistical significance was observed for water-treated WT vs simvastatin-treated 
WT (n=13). D, Severity index of AAAs of AngII-infused WT and Nf1+/– mice treated with water (WT, n=17; Nf1+/–, n=22) or simvastatin (WT, 
n=9; Nf1+/–, n=10). For B through D, saline-infused WT or Nf1+/– mice in either treatment group did not form aneurysms. AAA indicates 
abdominal aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error of the mean; and WT, wild type.
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To determine the contribution of neurofibromin-defi-
cient myeloid cells to Nf1+/– aneurysm formation, we used 
 lineage-restricted transgenic mice to specifically ablate a 
single Nf1 allele in myeloid cells alone. Heterozygous inacti-
vation of the Nf1 gene in myeloid cells was sufficient to repro-
duce the aneurysm phenotype observed in Nf1+/– mice infused 
Figure 6. Preventive effect of apocynin on AngII-induced AAA formation in Nf1+/– mice. A, Representative photographs of abdominal 
aortas from water or apocynin-treated, AngII-infused WT and Nf1+/– mice. Scale bars, 1 mm. B, Quantification of aneurysm incidence in 
water- or apocynin-treated, AngII-infused mice. *P<0.0083 for water-treated Nf1+/– (n=23) vs apocynin-treated Nf1+/– (n=26). Analysis by 
Fisher exact test with Bonferroni correction. C, Maximum abdominal aortic diameter of water- or apocynin-treated, AngII-infused WT 
and Nf1+/– mice. Clustering around 1 mm represents animals without aneurysm formation. *P<0.05 for water-treated WT (n=14) vs  water-
treated Nf1+/– (n=23). **P<0.05 for water-treated Nf1+/– vs apocynin-treated Nf1+/– (n=26). Analysis by 1-way ANOVA with the Tukey test. 
Error bars=mean±SEM. For B and C, no statistical significance was observed for water-treated WT versus apocynin-treated WT (n=24). 
D, Severity index of AAAs of AngII-infused WT and Nf1+/– mice treated with water (WT, n=14; Nf1+/–, n=23) or apocynin (WT, n=24; Nf1+/–, 
n=26). For B through D, saline-infused WT or Nf1+/– mice in either treatment group did not form aneurysms. AAA indicates abdominal 
aortic aneurysms; AngII, angiotensin II; ANOVA, analysis of variance; SEM, standard error of the mean; and WT, wild type.
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with AngII. Importantly, despite significant expansion of 
Nf1+/– VSMCs in arterial walls, aneurysm frequency and sever-
ity in transgenic mice harboring a single Nf1 allele in VSMCs 
alone were similar to WT controls. Additionally, administra-
tion of simvastatin, a statin with potent  anti-inflammatory and 
antioxidant effects, diminished aneurysm formation in Nf1+/– 
mice. Finally, the antioxidant apocynin efficiently reduced 
Nf1+/– aneurysm formation. Collectively, these data directly 
implicate neurofibromin-deficient myeloid cells as the critical 
cellular effectors of aneurysm formation in Nf1+/– mice and 
indicate ROS as a therapeutic target to prevent or treat NF1 
aneurysm formation.
Neurofibromin negatively regulates the Ras signaling cas-
cade in multiple cell types by accelerating the conversion of 
active Ras-GTP to its inactive GDP confirmation.1 Loss of 
neurofibromin activates Ras and its downstream effectors, 
including the Ras-Mek-Erk and Ras-PI-3K pathways, render-
ing cells hypersensitive to diverse growth factors, contributing 
to the complexity of disease manifestations observed in NF1 
patients.2,8,9,17 Interestingly, myeloid progenitor cells are par-
ticularly sensitive to Ras activation and demonstrate multiple 
gain-of-function phenotypes contributing to myeloprolifera-
tive disease, plexiform neurofibroma formation, bone disease, 
and vaso-occlusive disease in animal models of NF1 dis-
ease.8,9,27–29 Relevant to the current study, myeloid cells secrete 
growth factors and cytokines that are mediators of CVD, 
including vessel occlusion and aneurysm formation.9,30 In 
view of our recent report that neurofibromin-deficient myeloid 
cells are the primary mediators of Nf1+/– arterial stenosis,9 the 
observation that mice with heterozygous inactivation of Nf1 in 
myeloid cells alone form aneurysms at a similar incidence to 
Nf1+/– mice highlights the global pathogenic consequences of 
neurofibromin-deficient myeloid cells to diverse NF1 clinical 
manifestations, including CVD.
Myeloid cell recruitment and infiltration of the vessel 
wall to initiate elastic lamina degradation are essential steps 
in aneurysm formation.25 AngII facilitates aneurysm for-
mation via activation of monocytes and other leukocytes, 
which secrete cytokines and chemotactic factors leading to 
enhanced macrophage production of MMPs, resulting in vas-
cular inflammation and vessel wall remodeling.31 Although 
several molecular ligand-receptor signaling cascades contrib-
ute to the progression of aneurysmal disease, pharmacologi-
cal inhibition or genetic disruption of monocyte chemotactic 
protein-1 binding to its primary receptor, CCR2, reduces 
aneurysm formation and MMP-2 and MMP-9 activation, 
as well.31–33 This signaling axis is particularly interesting 
because our laboratory recently demonstrated that myeloid 
cell heterozygosity mobilized Ly6Chi monocytes in periph-
eral blood,9 which are the murine correlate of human proin-
flammatory monocytes and coexpress high cell surface levels 
of the CCR2 receptor.34,35 Whether Nf1+/– macrophages are 
mobilized from the bone marrow via the monocyte chemo-
tactic protein-1/CCR2 axis or proliferate locally within the 
aortic wall from the recently described common myeloid pro-
genitor remains to be elucidated.31,36
Another striking observation in our study is the increased pro-
duction of ROS and MMPs in Nf1+/– vessel walls and develop-
ing aneurysms. ROS and MMP production by various cell types 
is critical for aneurysm formation in several model systems. 
Genetic or pharmacological disruption of MMP-2 and MMP-9 
in mice decreases aneurysm formation.37 These findings sug-
gest that MMPs, released by resident and infiltrating vascular 
wall cells, are key molecular events in aneurysm formation. 
Given these observations, our study suggests that increased lev-
els of MMP-9 observed in Nf1 heterozygous aneurysms may 
play a significant role in NF1 aneurysm progression, warranting 
further investigation to examine whether genetic modification 
and pharmacological inhibition of MMP-9 activity can inhibit 
aneurysm progression in our Nf1 experimental system.
Increased ROS levels are also detected in human and 
murine cardiovascular lesions including aneurysms.38,39 
Moreover, evidence suggests that ROS overproduction facili-
tates MMP activation and contributes to vascular inflamma-
tion and vessel wall remodeling.40 Neurofibromin directly 
stimulates the adenylyl cyclase/cAMP pathway, whereas loss 
of neurofibromin amplifies mitochondrial ROS production in 
Drosophila melanogaster.41 Conversely, constitutively active 
Ras mutations dramatically increase ROS production in mam-
malian hematopoietic progenitor cells via NAD(P)H oxidase 
(NOX) activation without increasing mitochondrial ROS.42 
Additionally, we have found that simvastatin and apocynin, 
which both have antioxidant properties, reduce Nf1+/– aneu-
rysms, implicating oxidative stress as a major contributor 
to  neurofibromin-deficient aneurysm formation.21,23 Further 
investigation using complex transgenic mice and targeted 
pharmacotherapies will now be needed to explore the redox 
balance in neurofibromin-deficient cells and to determine the 
source of ROS in aneurysm pathogenesis.
Previous studies have also identified increased expression 
of ROS-producing NOX subunits p22phox and p47phox within 
aortic aneurysms of non-NF1 patients and mice.38,43 Genetic 
disruption of p47phox significantly diminishes oxidative stress 
and subsequent aneurysm formation in mice infused with 
AngII.26 These data suggest a role of NOX proteins as pro-
ducers of ROS in aneurysm pathogenesis, indicating potential 
sources for observed Nf1+/– ROS production. Interestingly, 
Heumuller et al23 extensively studied apocynin’s ability to 
reduce ROS in infiltrating and resident vascular wall cells, 
concluding that apocynin is dimerized and activated in 
 myeloperoxidase-expressing cells, including macrophages and 
granulocytes. Apocynin’s dimerized form is believed to inhibit 
the binding of the p47phox cytosolic subunit to the membrane-
bound gp91phox subunit, therefore inhibiting the formation of 
the active NOX2 complex.44 These studies provide a rationale 
for transgenic murine studies using  cell-specific deletion of 
p47phox and gp91phox within endothelial cells, VSMCs, and 
monocytes/macrophages in Nf1+/– mice to test whether spe-
cific NOX isoform(s) contribute to ROS overproduction and 
aneurysm development. These studies are currently underway 
in our laboratory to identify specific therapeutic targets for 
preventing and treating NF1 vascular disease.
Statins are efficacious in reducing inflammation and oxi-
dative stress independent of their lipid-lowering capacity in 
both human trials and animal models.21 Additionally, statins 
have a safety profile that makes them advantageous for use in 
pediatric patients, as evidenced by recent trials in NF1 chil-
dren,45 which may be important because evidence of vascular 
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inflammation was identified in adolescent NF1 patients.8 In 
the current study, simvastatin reduced Nf1+/– aneurysm for-
mation with corresponding attenuation of MMP-9 activation 
and ROS production, lending evidence to the role of inflam-
mation and oxidative stress in NF1 aneurysm development. 
Finally, treatment with the antioxidant apocynin, which pro-
duced results similar to simvastatin, indicates that a reduction 
of oxidative stress may mediate the therapeutic effect simvas-
tatin has on reducing Nf1+/– aneurysm formation. Based on our 
preclinical findings that low-dose statin treatment attenuates 
aneurysm formation and vaso-occlusive disease,9 it is possible 
that statins or more general antioxidants could be a viable 
therapeutic intervention in NF1 patients for the prevention and 
treatment of CVD.
In sum, this study establishes the first animal model of NF1 
aneurysm disease and identifies Nf1 heterozygous myeloid 
cells as the cellular effectors of Nf1+/– aneurysm formation. 
In addition, we provide significant evidence that oxida-
tive stress partially mediates Nf1+/– aneurysm formation and 
may be a viable therapeutic target. We provide a new model 
of NF1 vasculopathy that will serve as a tractable platform 
for understanding disease pathogenesis, the identification of 
novel biomarkers of preclinical disease, and the development 
of novel therapeutics for the prevention and treatment of NF1 
aneurysm formation.
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CLINICAL PERSPECTIVE 
Neurofibromatosis type 1 (NF1) is a common genetic disorder resulting from mutations in the NF1 tumor suppressor gene. 
Although malignancy and neoplasia are common manifestations of NF1, cardiovascular disease is an underrecognized 
source of significant morbidity and premature mortality in NF1 patients. NF1 patients have increased propensity for the 
development of profound arterial disease, including renal and carotid stenosis, aneurysms, and cerebrovascular disease. In 
this study, we present the first animal model of Nf1 aneurysm formation by using a well-described transgenic mouse line. 
These Nf1 aneurysms demonstrate increased infiltration of myeloid cells, inflammatory changes, and production of reactive 
oxygen species, which are characteristic of aneurysms in the general population. Based on these observations, we provide 
novel evidence that Nf1 aneurysms are significantly reduced by daily, low-dose statin administration and antioxidant therapy, 
which may be mediated through diminished myeloid cell interactions with the vascular wall and reduced reactive oxygen 
species production. For the clinician, NF1 represents an important risk factor for multiple forms of cardiovascular disease, 
and early recognition and treatment may prevent premature mortality in this patient population.
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Supplemental Methods 
 
 
Histopathology and immunohistochemistry 
Aortas were paraffin embedded and serial 5µm cross-sections were made through the length of 
the aorta at its largest diameter. Sections were stained with H&E (Anatech), Verhoeff's van Gieson 
(Sigma) for elastic lamina, Masson's trichrome (Sigma) for collagen, and Toluidine blue (Anatech) for 
mast cells. Elastic lamina preservation was graded as follows: grade 1, intact elastic lamina; grade 2, 
elastic lamina with some interruptions; and grade 3, severe elastin fragmentation. For 
immunohistochemistry, paraffin-embedded sections were de-waxed followed by enzymatic antigen 
retrieval (20µg/ml Proteinase K; Roche). Sections were Protein Blocked (Dako) and incubated separately 
with anti-CD3 (1:100, BD Pharmingen), anti-B220 (1:100, BD Pharmingen), anti-alpha smooth muscle 
actin (α-SMA, 1:200, Abcam), anti-Mac-3 (1:50, BD Pharmingen), anti-MMP2 (1:2000, Abcam) and 
anti-MMP9 (1:1000, Abcam) primary antibodies. Sections were incubated with the appropriate 
biotinylated secondary antibody (Vector Laboratories) followed by incubation with the ABC kit (Vector 
Lab), and visualized by 3,3’-diaminobenzidine (DAB; Vector Laboratories) and counterstained with 
hemotoxylin. The average number of CD3+, B220+, F4/80+, Mac-3+ and mast cells were calculated from 
five independent high-power fields from five sections at 50µm intervals. Some cross-sections were co-
stained with fluorescent α-SMA and anti-Mac-3. 
 
Matrix metalloproteinase activity analysis 
In situ zymography and gelatin zymography were performed as previously described.1 For in situ 
zymography, frozen optimum cutting temperature (OCT)-embedded aortic sections (10µm) from 18-day 
saline or AngII-infused WT and Nf1+/- mice were incubated with a dye-quenched gelatin substrate (DQ-
gelatin, Molecular Probes) according to the manufacturer’s protocol. After cleavage of DQ-gelatin by 
gelatinolytic activity, green fluorescence was photographed by fluorescence microscopy. Addition of 
EDTA (20 mM), a negative control for MMP-2 and 9 activity, in gelatin substrate was used to assess the 
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specificity of MMP activity. For gelatin zymography, 10 µg of homogenates lysed from segments of aorta 
from 18-day saline or AngII-infused WT and Nf1+/- mice were electrophoresed in a 10% SDS-
polyacrylamide gel containing 1 mg/mL gelatin (Invitrogen). Gels were incubated for 36 hours in 
zymography buffer and stained with Coomassie brilliant blue followed by destaining to visualize bands.  
 
In situ superoxide detection 
In situ dihydroethidium (DHE) staining was performed as described2. Cross-sections (10 µm) of 
OCT-embedded aortas were incubated with DHE (5 µM) (Molecular Probes Inc.) for 30 minutes and 
photographed using fluorescent microscopy. Mean fluorescence intensity of the digital images was 
quantified in the aorta at is widest point using Image J software (version 1.46, NIH). 
 
 
 
 
 
 
 
 
 
 
 
 
  
	   4	  
Supplemental References 
 
 
1. Satoh K, Nigro P, Matoba T, O'Dell MR, Cui Z, Shi X, Mohan A, Yan C, Abe J, Illig KA, Berk 
BC. Cyclophilin a enhances vascular oxidative stress and the development of angiotensin ii-
induced aortic aneurysms. Nature medicine. 2009;15:649-656. 
2. Tieu BC, Lee C, Sun H, Lejeune W, Recinos A, 3rd, Ju X, Spratt H, Guo DC, Milewicz D, Tilton 
RG, Brasier AR. An adventitial il-6/mcp1 amplification loop accelerates macrophage-mediated 
vascular inflammation leading to aortic dissection in mice. The Journal of clinical investigation. 
2009;119:3637-3651. 
 
 
  
	   5	  
Supplemental Figure 1 
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Supplemental Figure 1. AngII infusion results in increased vascular smooth muscle cell density in 
Nf1+/- mice. (A) Representative photomicrographs of abdominal aortic cross-sections from AngII-infused 
WT and Nf1+/- mice, stained with anti-alpha smooth muscle actin (red) to identify VSMCs. Cell nuclei are 
counterstained with DAPI (blue) and auto-fluorescence of murine tissue is visible (green). Saline-infused 
WT mice shown as control. Appearance of saline-infused Nf1+/- was similar to saline-infused WT 
staining. Scale bars: 50µm.  (B) Quantification of VSMCs from AngII-infused WT (n=5) and Nf1+/- (n=5) 
mice; *P<0.05 for AngII-infused WT versus AngII-infused Nf1+/-, by Student’s t-test. (C) Representative 
photomicrographs showing co-staining of AngII-infused WT and Nf1+/- aortas with anti-α-SMA (red) and 
anti-Mac-3 (green). Scale bars: 50µm 
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Supplemental Figure 2 
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Supplemental Figure 2. Cre-mediated ablation of a single Nf1 allele in myeloid cells alone 
recapitulates AAA formation in Nf1+/- mice. (A) Representative photomicrographs of abdominal aortic 
cross-sections from AngII-infused WT, Nf1+/-, Nf1flox/+;LysMcre and Nf1flox/+;SM22cre, stained with H&E 
or (B) van Gieson for elastin. Boxes identify area that is magnified in lower panel. Arrowheads identify 
fragmentation of elastic lamina in van Gieson photomicrographs and yellow staining identifies 
extracellular matrix. Saline infusion did not produce aneurysms in any genotype (data not shown). Scale 
bars: 50µm. (C)	  Grading of elastic lamina degradation in AngII-infused Nf1flox/+;LysMcre and 
Nf1flox/+;SM22cre mice. *P<0.05 for Nf1flox/+;LysMcre (n=12) versus Nf1flox/+;SM22cre (n=9). No 
statistical significance in elastic lamina degradation grade was observed between Nf1flox/+;LysMcre and 
Nf1+/- mice or Nf1flox/+;SM22cre and WT mice (data not shown). (D)	  Representative	  photomicrographs	  showing	  MMP	  activity	  in	  Nf1flox/+;LysMcre and Nf1flox/+;SM22cre mice.	  Scale bars: 50µm. (E) Representative	  photomicrographs	  of	  abdominal	  aortic	  cross-­‐sections	  from	  saline	  or	  AngII-­‐infused	  WT	  and	  Nf1+/-­‐	  mice,	  showing	  superoxide	  production	  identified	  by	  in	  situ	  DHE	  staining	  (red).	  Auto-­‐fluorescence	  of	  murine	  tissue	  is	  visible	  (green).	  Scale bars: 50µm. 	  Bar	  graph	  depicts	  quantification	  of	  ethidium	  fluorescence.	  (F) PCR analysis of abdominal aorta shows the specific location of the cre-
mediated recombination of floxed Nf1 gene in the vascular adventitia of 3 month old, non-infused 
Nf1flox/+;LysMcre mice. Arrowhead indicates cre-mediated recombination (280bp band). Nf1flox/+;SM22cre 
VSMCs were used as positive control.  
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Supplemental Figure 3 
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Supplemental Figure 3. Simvastatin prevents AngII-induced AAA formation in Nf1+/- mice. (A) 
Representative photomicrographs of abdominal aortic cross-sections from water or simvastatin-treated, 
AngII-infused WT and Nf1+/- mice stained with H&E, van Gieson for elastin or (B) anti-Mac-3 
(arrowheads). Boxes specify area magnified in lower panel. Saline-infused WT and Nf1+/- mice treated 
with water or simvastatin did not produce aneurysms (data not shown). In A, arrowheads identify 
fragmentation of elastic lamina and yellow staining identifies extracellular matrix. Scale bars: 50µm.  
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Supplemental Figure 4 
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Supplemental Figure 4. Simvastatin attenuates MMP expression and activation and ROS 
production induced by AngII in Nf1+/- mice. (A) Representative photomicrographs of abdominal aortic 
cross-sections from water or simvastatin treated, AngII-infused WT and Nf1+/- mice. MMP activity 
(green) was visualized by in situ zymography and expression of MMP-2 and MMP-9 was detected by 
immunohistochemical staining with anti-MMP-2 (brown) and anti-MMP-9 antibodies (brown). Scale 
bars, 50µm. (B) Representative zymogram showing abdominal aortic MMP-2 and MMP-9 levels from 
water or simvastatin treated, AngII-infused WT and Nf1+/- mice. (C) Representative photomicrographs of 
abdominal aortic cross-sections from water or simvastatin treated, AngII-infused WT and Nf1+/- mice 
showing ROS identified by in situ DHE staining (red). Autofluorescence of murine tissue is visible 
(green). (D)	  Quantification	  of	  ethidium	  fluorescence	  for	  simvastatin-­‐treated,	  AngII-­‐infused	  WT	  and	  
Nf1+/-­‐. 
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Supplemental Figure 5 
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Supplemental Figure 5. Apocynin prevents AngII-induced AAA formation in Nf1+/- mice. (A) 
Representative photomicrographs of abdominal aortic cross-sections from water or apocynin-treated, 
AngII-infused WT and Nf1+/- mice stained with H&E, van Gieson for elastin or (B) anti-Mac-3 
(arrowheads). Boxes specify area magnified in lower panel. Saline-infused WT and Nf1+/- mice treated 
with water or apocynin did not produce aneurysms (data not shown). In A, arrowhead identifies 
fragmentation of elastic lamina and yellow staining identifies extracellular matrix. Scale bars: 50µm. (C) 
Representative photomicrographs of abdominal aortic cross-sections from water or apocynin treated, 
AngII-infused WT and Nf1+/- mice showing ROS identified by in situ DHE staining (red). Auto-
fluorescence of murine tissue is visible (green). (D)	  Quantification	  of	  ethidium	  fluorescence	  for	  apocynin-­‐treated,	  AngII-­‐infused	  WT	  and	  Nf1+/-­‐.	   
 
